Study title: Efficacy of Symbicort® Turbuhaler® 160/4.5 µg as needed versus Oxis® 4.5 µg as needed and Bricanyl® 0.4 mg as needed in adults and adolescents with asthma receiving Symbicort® Turbuhaler® 160/4.5 µg twice daily as maintenance treatment. A 12-month, randomised, double-blind, parallel-group, active-controlled, phase IIIB, multi-centre study.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Respiratory Tract Diseases [C08] | |||||
| Brands: | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: BUDESONIDE AND FORMOTEROL | |||||
| ATC code: | |||||
| Document link: LD-039-0003 CSR Synopsis.pdf | |||||
| Document date: 2011-09-15 | |||||
| Study number: LD-039-0003 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | Y | |